Structural determinants and genetic modifications enhance BMP2 stability and extracellular secretion.

Area of Science:

• Biochemistry
• Molecular Biology
• Regenerative Medicine

Background:

• Recombinant bone morphogenetic protein-2 (BMP2) has limitations in clinical use due to its short half-life and required high doses.
• Intracellular processing, degradation, and secretion mechanisms of BMP2 are not fully understood.

Purpose of the Study:

• To identify mechanisms regulating intracellular BMP2 stability.
• To explore strategies for enhancing BMP2 stability and secretion for potential therapeutic applications.

Main Methods:

• Inhibition of proteasomal degradation pathways.
• Identification of BMP2 degradation as an ubiquitin-mediated process.
• Systematic mutation of lysine residues in BMP2 to assess stability and secretion.
• Structural modeling to identify key lysine residues involved in degradation.

Main Results:

• Inhibiting proteasomal degradation increased intracellular BMP2 levels and extracellular secretion.
• BMP2 degradation is mediated by ubiquitination, primarily on lysine residues.
• Mutations in four pro-BMP2 and three mature BMP2 lysine residues enhanced BMP2 turnover and secretion.
• Mutated lysine residues involved in degradation were located near the proprotein convertase cleavage site.
• Mutations did not impact the biological activity of BMP2.

Conclusions:

• Genetic modification of specific lysine residues can enhance BMP2 stability and secretion.
• This approach offers a potential strategy to overcome the limitations of BMP2's short half-life.
• Targeting intracellular degradation pathways presents a novel therapeutic avenue for BMP2 applications.